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The BUAV and European Coalition to End Animal Experiments 
 
Established in 1898, the British Union for the Abolition of Vivisection (BUAV) is the 
world’s leading organisation campaigning peacefully to end all animal experiments. As 
Chair of the European Coalition to End Animal Experiments (ECEAE), the BUAV liaises 
with key animal groups across Europe to co-ordinate campaigning initiatives and ensure 
that laboratory animals are high on the European political agenda. As a founding 
member of the International Council for Animal Protection in OECD Programmes 
(ICAPO), the BUAV joins with animal protection groups across Europe, the United 
States and Japan to ensure that laboratory animals have an effective voice within the 
Organisation for Economic Co-operation and Development, as it co-ordinates 
international testing guidelines that affect laboratory animals around the world. 
 
Acute Toxicity Testing Without Animals 
 
The BUAV has led the campaign to eliminate animal testing from the European Union’s 
REACH chemicals strategy. Whilst we fully support the aim of improving chemicals 
regulation to protect human health and the environment, we believe that the use of 
animal testing will inflict immense and needless suffering while failing to provide the 
reliable information essential to achieving that end. 
 
Throughout discussions of the REACH proposals, the BUAV and ECEAE have been 
campaigning for the use of non-animal testing strategies, mandatory data-sharing and 
increased funding for the development and validation of further non-animal tests. We 
have contributed to expert working groups, consultations and stakeholder conferences, 
and thus have been instrumental in ensuring that animal suffering is not forgotten as the 
EU and its member countries strive for more effective chemicals regulation. This work is 
not only helping to guarantee that every opportunity is taken to ensure that the proposal 
contains the most humane and effective science available but is also shaping the wider 
debate about animal toxicity testing at an international level. 
 
The BUAV has published a series of influential reports on the use of animal toxicity tests. 
These include The Way Forward, a comprehensive non-animal testing strategy, in 2001, 
and, in 2004, A Regulatory Smokescreen presenting an analysis of the systemic failings 
of animal toxicity testing in chemicals regulation. These are available on our website 
(see below). 
 
This report, the latest in that series, targets the specific issue of acute toxicity testing. 
 
British Union for the Abolition of Vivisection 
16a Crane Grove 
London 
N7 8NN 
Tel: +44 (0)20 7700 4888 







Since the early days of the REACH proposals, it has been accepted by all parties that 
the numbers of animals used to gain toxicity information on chemicals should be kept to 
an absolute minimum.  
 
In its ground-breaking and influential report, The Way Forward — A Non-Animal Testing 
Strategy for Chemicals1, the BUAV and ECEAE argued that animal test data should not 
be part of the new chemicals policy.2 The reasons include the suffering caused to 
animals by testing; the unreliability of animal (usually rodent) data when extrapolating to 
humans; the ways that animal data can obstruct regulatory decision-making3; and the 
cost and delays that would be caused by seeking animal data. 
 
In this report, we argue specifically that acute toxicity data should not be sought from 
animal tests. The underlying principle of such tests on rats and mice is that the results 
can be effectively extrapolated to humans. In fact, after nearly 80 years of use of these 
tests, the predictivity of rodent data for human acute toxic effects has been disputed but 
never proven. 
 
Tests, in which animals are poisoned to death, have no place in a 21st Century 
chemicals policy. There is already evidence that in vitro and in silico methods for acute 
toxicity are able to provide sufficient data for classification and labelling purposes, and 
further rapid advances in the field of non-animal research will be achieved as resources 
are made available.   
 
As Erik Walum of the University of Stockholm wrote4: 
 
“The value of the prediction of acute human toxicity based on this 
information will depend on the similarity between the test species and man 
in all the events involved. ...The modelling of quantitative toxicity in vitro is 
more scientific and less of a gamble. It involves a multiple analysis of many 
                                                 
1 BUAV (2001). The Way Forward — A Non-Animal Testing Strategy for Chemicals. Publ. BUAV 
& the European Coalition to End Animal Experiments, London. 
2 In July 2003, two years after our report The Way Forward was published, the European 
Commission’s DG Environment referred it to the Scientific Committee on Toxicity, Ecotoxicity and 
the Environment (CSTEE) for a detailed opinion. 
The opinion [CSTEE (2004). Opinion of the Scientific Committee on Toxicity, Ecotoxicity 
and the Environment on the BUAV-ECEAE report on The Way Forward – Action to End Animal 
Toxicity Testing. Brussels, C7/VR/csteeop/anat/080104 D(04)] included criticisms of our report 
but the basis and validity of these criticisms was surprising and often unfounded. The CSTEE 
failed to consider the BUAV’s recommendations in the proper context of the 7-point action plan 
we had proposed, and thus misrepresented our proposals. Criticisms that The Way Forward did 
not take dose/response relationships into account were fully refuted [BUAV response to the 
CSTEE criticisms of The Way Forward. February 2004. Publ. BUAV]. 
The CSTEE made extraordinary and unsubstantiated claims for the validity of animal 
tests, contradicting the views of many other experts, including ECVAM. We provided specific, 
well-referenced critiques in our original report which we expanded in our rebuttal. 
3 G Langley (2004). Chemical Safety and Animal Testing: A regulatory smokescreen? A BUAV 
Report, publ. BUAV/ECEAE, London. 
4 E Walum (1991). Acute Toxicity Testing. In: Animals and Alternatives in Toxicology. Eds: M 
Balls et al. Publ. FRAME, Nottingham. 
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parameters, which can be studied separately or in combination — a 
procedure which can be designed to fit the questions asked. ...Each piece 
of evidence can be evaluated in terms of its relevance for the 
corresponding human event.” 
 
This report aims to expose the scientific weaknesses of animal tests for acute toxicity; 
inform readers as to the extent of animal suffering caused by these crude and outdated 
tests, and to propose non-animal alternative test strategies. 
 
2. The Case Against Acute Toxicity Tests on Animals 
 
For many decades, chemicals were routinely classified for acute toxicity by the LD50 
test, which requires the poisoning of many animals per chemical. For testing by the oral 
route, the LD50 method has been deleted from OECD test guidelines in favour of 
protocols using fewer animals. These include the Fixed Dose Procedure, the Acute 
Toxic Class Test and the Up-and-Down Procedure, which provide an estimated LD50 
value.  
 
However, for dosing by the dermal (skin) route and by inhalation, the LD50/LC50 tests 
are still the norm. This means that many animals are still being poisoned to death using 
a highly-criticised method essentially unchanged since the late 1920s (see below). 
Twenty-first century science must surely be capable of greater sophistication (and 
humanity) than this. 
 
Acute toxicity refers to the effects on the whole body of a single dose of a chemical (or 
several doses within a 24-hour period), usually manifested over a period of 14 days.  
 
Acute toxicity data are used mainly to:  
 
i] Identify lethal/toxic doses of chemicals for humans (primarily for the regulatory 
purposes of classification and labelling);  
ii] Indicate the mode of toxicity in humans, including the susceptibility of key target 
organs; and  
iii] Provide a rough guide for dose selection in repeat-dose tests in animals.  
 
From the regulatory point of view, acute toxicity data are mainly required for classifying 
and labelling chemicals according to their intrinsic toxicity5, with the aim of allowing their 
safe transport and the protection of people handling and using them. This aim is 
frustrated by species differences, and can be achieved by non-animal methods (see 
Section 6). Further, worker and consumer exposures are most commonly at a low-dose, 
repetitive level rather than by a single, massive dose. 
 
For identifying target organ susceptibility, acute toxicity tests on animals are of limited 
relevance to people, partly because of variations between species in the way they deal 
with and react to chemicals. Autopsy of animals may highlight major affected target 
                                                 
5 L Gribaldo et al (2004). Report for establishing the timetable for phasing out animal testing for 
the purpose of the cosmetics directive. Acute Toxicity Chapter. European Commission DG 
Enterprise website: http://pharmacos.eudra.org/F3/cosmetic/AnimalTest.htm 
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organs, but these are usually liver and/or kidney because they receive the highest 
chemical exposure6. Similar information could be obtained from in vitro studies. 
 
Zbinden and Flury-Roversi7 compared lethal dose values from animal tests with those 
discovered in cases of accidental human poisoning, and concluded: 
 
“For the recognition of symptomatology of acute poisoning in man, and for 
the determination of the human lethal dose, the LD50 in animals is of very 
little value.” 
 
For dose selection for repeat-dose studies, acute toxicity data can provide a rough 
guide. However non-animal methods, for example human cell culture approaches, would 
allow in vitro repeat-dose studies to be conducted rapidly and without the problems of 
species extrapolation, cost and delay incurred by animal tests. 
 
For example, under the EU Framework Programme 6 a project called PREDICTOMICS 
is being funded to develop short-term in vitro assays for long-term toxicity8. This will be 
achieved using co-cultures of resident cell types, target cell transformation, stem cell 
technology and new developments in organotypic cell culture. The project aims to 
identify specific early mechanistic markers of toxin-induced cell alterations by using 
integrated genomic, proteomic and cytomic analysis; and to establish and prevalidate a 
screening platform (cell systems together with analysis tools) which is unambiguously 
predictive of toxin-induced chronic renal and hepatic disease.  
 
2.1 Human relevance of acute toxicity tests on animals 
 
The most important limitations of animal tests are the wide variations in responses 
caused by species and strain differences. These variations occur in sensitivities to toxic 
chemicals as well as in rates and routes of metabolism and in absorption, distribution 
and excretion.  
 
All animal studies conducted in the hopes of protecting human health have this critical 
weakness. As Garattini wrote, concerning the difficulties of extrapolating from animals to 
humans 9: 
 
“A third problem concerns the difference in various animal species in the 
biological substrates on which chemicals exert their toxic effects. Equal 
concentrations of chemicals and their metabolites do not mean equal toxic 
effects across animal species because endogenous metabolic processes, 
cell permeability, enzymes, and receptors are not necessarily the same in 
animals and man.” 
 
                                                 
6 SM Barlow et al (2002). Hazard identification by animal-based methods of toxicology. Food & 
Chem. Toxicol. 
7 G Zbinden & M Flury-Roversi (1981). Significance of the LD50 test for the toxicological 
evaluation of chemical substances. Archives Toxicol. 47:77-99. 
8 http://fp6.cordis.lu/fp6/home.cfm  
9 S Garattini (1985). Toxic effects of chemicals: difficulties in extrapolating data from animals to 
man. Crit. Rev. Toxicol. 16:1-29. 
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Acute toxicity tests on animals, whether using the LD50 or other protocols, have never 
undergone formal validation to modern standards10 to establish their relevance for 
humans. As Ekwall and colleagues said of the LD50 test11,  
 
“The test has never been formally validated. The widespread use of the test 
has therefore not been based on a documented good performance, but on 
the lack of better tests.” 
 
The LD50 test itself was designed in 1927 for the purpose of standardising biological 
preparations, and then adapted for testing the acute toxicity of chemical substances. 
Concern about species and strain variations was first expressed many decades ago and 
continues to the present day.  
 
For historical reasons, many of the criticisms were made of the original LD50 test, but 
those cited here are equally valid for modified oral toxicity tests including the Fixed Dose 
Procedure, the Acute Toxic Class and the Up-and-Down Procedure, as well as the LD50 
(dermal) and LC50 (inhalation) methods, which are still in use today.  
 
The Physicians Committee for Responsible Medicine12 illustrate the problem by means 
of a table comparing LD50 values for rats and mice for 10 substances: 
 
 
Comparison of LD50 values in rats and mice 
(NIOSH/Registry of Toxic Effects of Chemical Substances) 
 






Carbon tetrachloride 2,350 8,260 0.28 
Dextropropoxyphene HCl 84 225 0.37 
Dichloromethane 1,600 873 1.8 
Diphenylhydantion 1,640 150 10.9 
Ethanol 7,060 3,450 2.0 
Mercury (II) Chloride 1 6 0.17 
Nicotine 50 3 16.7 
Paracetamol 2,400 340 7.0 
Sodium oxalate 11,200 5,100 2.2 
Thioridazine HCl 995 385 2.6 
 
 
There are many other examples: acetaminophen is fatal to mice at 250-400 mg/kg 
causing death through liver necrosis. In rats the LD50 value is about 1,000 mg/kg but 
there is little sign of liver damage13. Mice and rats show significant species differences in 
                                                 
10 OECD (1996). Final report of the Solna Workshop on validation and regulatory acceptance 
criteria for alternative tests. OECD report ENV/MC/CHEM/TG(96)9. 
11 B Ekwall et al (1998). MEIC evaluation of acute systemic toxicity. Part VI. The prediction of 
human toxicity by rodent LD50 values and results from 61 in vitro methods. ATLA 26:617-658. 
12 PCRM (1999). Website: www.pcrm.org/resch/anexp/LD50.html [visited December 2004]. 
13 DJ Jollow et al (1974). Acetaminophen-induced hepatic necrosis. VI. Metabolic disposition of 
toxic and non-toxic doses of acetaminophen. Pharmacol. 12:251-271. 
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response to naphthalene14. The LD50 value for thiourea in the Hopkins strain of rat is 4 
mg/kg, but in the wild Norway rat is 1,830 mg/kg15. 
 
Genomic research has revealed that, in evolutionary terms, rats and mice diverged as 
separate species between 18-24 million years ago. They are much more similar, 
genotypically and phenotypically, than are rodents and humans — who diverged 80 
million years ago. Differences in reactions to chemicals between closely related rats and 
mice demonstrate why acute toxicity tests on rodents have even more dubious 
predictivity for humans.  
 
A 1948 report found that the sensitivity of humans to chemicals was occasionally the 
same as measured in animals, but in general was higher. Large differences (up to 2,000-
fold) between humans and animals were typical16. As Gerhard Zbinden commented17: 
 
“...with such enormous variations, it is clear that the knowledge of the LD50 
in a mouse or a rat does not provide much support for the prognosis in a 
human case of acute poisoning.” 
 
The 1981 study by Zbinden and Flury-Roversi18, comparing animal lethal dose values 
with human poisoning data, revealed many discrepancies. For example, humans were 
1000 times more susceptible to atropine than predicted by animal tests, while laboratory 
animals were 15 times more sensitive to barbital.  
 
Lorke19 added in 1983 that: 
 
“...even if the LD50 could be measured exactly and reproducibly, the 
knowledge of its precise numerical value would barely be of practical 
importance, because an extrapolation from the experimental animals to 
man is hardly possible.” 
 
The Multicentre Evaluation of In vitro Cytotoxicity tests (MEIC) programme found that for 
50 reference chemicals, the rat LD50 values predicted values in mice well (correlation 
coefficient 0.88), but rat and mouse LD50 values predicted human acute lethal doses 
rather poorly (correlation coefficients 0.61 and 0.65 respectively)20.  
 
                                                 
14 DJ Quick & ML Shuler (1999). Use of in vitro data for construction of a physiologically based 
pharmacokinetic model for naphthalene in rats and mice to probe species differences. Biotechnol. 
Prog. 15:540-555. 
15 SH Dieke & CP Richter (1945). Acute toxicity to rats in relation to age, diet, strain, and species 
variation. J. Pharmacol. Exp. Ther. 83:195-202. 
16 R Müller (1948). Vergleich der im Tierexperiment und beim Menschen tödlichen Dosen 
wichtiger Pharmaka. Diss. Univ. Frankfurt/Main. 
17 G Zbinden (1984). Acute toxicity testing, purpose. In: Acute Toxicity Testing; Alternative 
Approaches. Ed. AM Goldberg. Publ. Mary Ann Liebert Inc., New York. 
18 G Zbinden & M Flury-Roversi (1981). Significance of the LD50 test for the toxicological 
evaluation of chemical substances. Arch. Toxicol. 47:77-99. 
19 D Lorke (1983). A new approach to practical acute toxicity testing. Arch. Toxicol. 54:275-287. 
20 B Ekwall et al (1998). MEIC evaluation of acute systemic toxicity. Part VI. The prediction of 
human toxicity by rodent LD50 values and results from 61 in vitro methods. ATLA 26 (Suppl. 
2):617-658. 
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The Olson report, published in 200021, reviewed animal toxicity test data and human side 
effects for 150 drugs. Comparisons were made between a wide range of toxic effects in 
animals and the significant toxicities actually found when humans were given the drug 
during clinical trials. The report therefore excluded side effects seen in animals but not in 
humans; and long-term side effects such as carcinogenicity or effects on reproduction 
(since these human toxicities cannot be assessed in relatively short-term clinical trials). 
 
Olson and colleagues found that results from rodent tests (mainly acute studies) only 
predicted 43 per cent of human effects. This appalling performance would have been even 
worse if carcinogenicity and toxicity to reproduction had been included in the comparison. If 
a non-animal method undergoing validation yielded results of such low predictivity, it would 
be considered totally unsuitable. 
 
It is hardly surprising that there are significant species differences in acute toxicity results, 
given the variations that exist in critical determinants of toxicity such as metabolism and 
bloodstream protein binding22. The spectrum and activities of crucial liver enzymes that 
detoxify chemicals, such as cytochrome P450 enzymes, vary from species to species23. For 
example, metabolism largely accounts for the difference in butadiene toxicity seen between 
rats and mice. In mice (compared to rats), peak concentrations of the chemical are 4-8 
times higher in the blood, 13-15 times higher in the lungs and 5-8 times higher in the liver24. 
 
Finally, most cases of acute poisoning involve children under five years of age. Their 
susceptibility is very different to that of adults, yet a study comparing newborn and adult 
animals found large variations in toxic effects related to developmental patterns that are 
species-specific and cannot be easily extrapolated to human infants25. 
 
For nearly 80 years an unproven assumption — that tests on rodents accurately predict 
toxicity in humans — has formed the mainstay of acute toxicity testing. Retrospective 
assessments have continued to cast serious doubts on the validity of the tests, 
especially their relevance to humans. It is unbelievable that unproven methods of toxicity 
testing that are eight decades old should be considered suitable to include in a 21st-
century chemical regulatory system. 
 
2.2 Reliability of acute toxicity tests on animals 
 
A 1964 study found the LD50 test to have unacceptably poor reproducibility26. Lethal 
dose tests using the inhalational and dermal routes, as well as other acute toxicity 
animal tests, also suffer from variability. 
 
                                                 
21 H Olson et al (2000). Concordance of the toxicity of pharmaceuticals in humans and in animals. 
Reg. Toxicol. Pharmacol. 32:56-67. 
22 T Marrs (1988). In: Perspectives in basic and applied toxicology. Ed. B Ballantyne. Publ. John 
Wight & Co., Bristol. 
23 JW Paxton (1995). The allometric approach for interspecies scaling of pharmacokinetics and 
toxicity of anti-cancer drugs. Clin. Exp. Pharmacol. Physiol. 22:851-854. 
24 MW Himmelstein et al (1996). Metabolism of 1,3-butadiene: inhalation pharmacokinetics and 
tissue dosimetry of butadiene epoxides in rats and mice. Toxicol. 113:306-309. 
25 E Goldenthal (1971). A compilation of LD50 values in newborn and adult animals. Toxicol. 
Appl. Pharmacol. 18:185-207. 
26 JF Griffith (1964) Toxicol. & Applied Pharmacol. 6:726-730. 
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In 1979 a European Community multi-laboratory trial of the test’s reproducibility showed 
that LD50 values for the same chemicals varied by 3-fold to 11-fold between different 
laboratories27.  
 
A non-animal test with reproducibility this poor would never be accepted as valid, and 
this performance is quite unacceptable as a means of protecting human health. 
 
 
LD50 values for five chemicals from a European Community  
multi-laboratory study28 
 
Substance LD50 (mg/kg) Ratio largest:smallest value 
I 46 – 522 11.3 
II 800 – 4,150 5.2 
III 350 – 1,280 3.7 
IV 805 – 5,420 6.7 
V 70 – 513 7.3 
 
 
There are many explanations for the poor reproducibility of acute toxicity tests on 
rodents. If different species (see above), strains and ages of animals29 are used by 
different laboratories, the results will be significantly affected. This is also true of 
differences in the weight30 and diet of animals. Other factors may include differences in 
technical ability of those conducting the tests, as well as variations in ambient 
temperature, the housing conditions of animals, humidity, noise and the light/dark cycle. 
 
2.3 Practicalities of acute toxicity testing on animals 
 
All chemical testing programmes relying on animal tests have proved dramatically more 
costly and time-consuming than envisaged.  
 
For example, the dedicated programme of chemical testing on animals solely for long-
term toxicity and carcinogenicity, conducted jointly by the US National Toxicology 
Program and the US National Cancer Institute, took 36 years to achieve results for only 
500 chemicals31.  
 
The OECD’s Screening Information Data Set (SIDS) programme requires limited 
information that includes acute and repeat dose tests, and reproductive and genetic 
toxicity tests, conducted mainly on animals. In ten years of international co-operation 
                                                 
27 WJ Hunter et al (1979). Intercomparison study on the determination of single administration 
toxicity in rats. J. Assoc. Official Analyt. Chemist. 62:864-873. 
28 D Lorke (1983). A new approach to practical acute toxicity testing. Arch. Toxciol. 54:275-287. 
29 SH Dieke & CP Richter (1945). Acute toxicity to rats in relation to age, diet, strain, and species 
variation. J. Pharmacol. Exp. Ther. 83:195-207. 
30 T Balazs et al (1972). Protection against the cardiotoxic effect of isoproterenol HCl by restricted 
food intake in rats. Toxicol. Appl. Pharmacol. 21:237. 
31 International Life Sciences Institute (1998). Assessing the toxicity of exposure to mixtures of  
disinfection by-products — research recommendations. ILSI:USA. 
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under the SIDS programme, only 60 chemicals had been evaluated32.  
 
Thus, even though acute toxicity data may be lacking for only a small percentage of 
phase-in substances under REACH (see Section 5), relying on animal tests will delay 
the timely regulation which human health protection demands. 
 
2.4 Animal suffering in acute toxicity tests 
 
Acute toxicity tests cause many animals to experience distress and serious illness, and 
even the Fixed Dose Procedure causes deaths. Lethality is still the endpoint in 
LD50/LC50 tests (i.e. dermal and inhalational routes), the Acute Toxic Class method and 
the Up-and-Down Procedure33.  
 
Symptoms experienced by test animals may include: 
 
Tremors, unsteady gait, breathlessness, lethargy, weight loss, loss of 
balance, convulsions, excessive salivation, intestinal distension, diarrhoea, 
lethargy, nasal or anal bleeding or discharge, coma and death. 
 
Anaesthetics and analgesics are never used and the tests last several days, so only 
euthanasia brings an end to this suffering. The OECD test guidelines state that animals 
“...that are moribund or suffering severe pain and distress must be humanely killed” (our 
emphasis). However, euthanasia would not be applied until animals are literally 
poisoned to the point of death, as humanely killed animals count as animals that died on 
test.  
 
It is inconceivable that techniques causing this level of suffering to sentient animals 
should be tolerated and even advocated. The success of REACH is partly dependent on 
its acceptability to the public, whose opposition to tests causing pain and distress is 
clear34.  
 
3. Classification and Labelling 
 
Acute toxicity tests are used to generate information on which classification and labelling 
decisions are based. Labels used vary from Category 1 (danger/fatal if swallowed/in 
contact with skin/inhaled) to Category 5 (warning/may be harmful if swallowed/in contact 
with skin/inhaled). The symbols used are familiar: skull and crossbones for categories 1 
– 3, with exclamation mark for category 4, and no symbol for category 5. Because labels 
must give clear messages in a simple form, detailed information about precise effects is 
not needed for this purpose. 
 
Traditionally, the ‘LD50’ value of chemicals has given information on degrees of toxicity. 
(LD50 stands for Lethal Dose 50%, meaning the dose at which half of the number of test 
animals die.) A chemical with a low LD50 value is highly toxic because a low dose will 
                                                 
32 AM Goldberg & H Spielmann (2000). High production volume (HPV) testing. Developments in 
Animal & Veterinary Sciences 31B:1639. 
33 SM Barlow et al (2002). Hazard identification by animal-based methods of toxicology. Food & 
Chem. Toxicol. 
34 Royal Commission on Environmental Pollution (2003). Chemicals in Products — Safeguarding 
the environment and human health. 24th report. Cm 5827. 
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kill an animal. Category 1 substances have an oral LD50 value of (less than or equal to) 
5 mg/kg, while category 5 substances have an oral LD50 value of (less than or equal to 
5000 mg/kg.  
 
Classification and labelling based on LD50 values has been in use for decades. Now, 
implementation of the Globally Harmonised System for Classification and Labelling 
(GHS) is well underway. This international system means that all participating countries 
will interpret test results in the same manner. In the area of acute toxicity, the GHS 
currently relies on data from animal tests but need not be test-specific. The system could 
be adapted to use non-animal data to inform classification and labelling decisions.  
 
In vitro and in silico tests for acute toxicity, as proposed in this report, will provide 
quantitative data that can be used to classify and label chemicals in the usual categories 
according to the GHS.  
 
4. High-throughput Prioritisation – Not Mass Animal Testing 
 
Since we published our non-animal testing strategy for chemicals, The Way Forward, in 
2001 support for chemical prioritisation on the basis of rapid screening has come from 
several organisations. The Danish Environmental Protection Agency has used (Q)SARs 
to list the hazardous properties, including acute oral toxicity, of some 47,000 chemicals35 
. They recommend a wider application of this approach.  
 
The British Royal Commission on Environmental Pollution, in its 2003 report36 on 
chemical regulation, also advocated a mass sorting approach based on existing data 
and computational techniques, together with some in vitro studies. The Royal 
Commission also argued that: 
 
“To avoid undue delay and unnecessary use of animal tests, the sorting 
process should not be delayed while experimental toxicity information in 
generated de novo. Indicators [of] toxicity and ecotoxicity can be derived 
from knowledge of chemical structure using various computational 
approaches. The US EPA’s procedure for assessing pre-market 
notifications is heavily reliant on the use of structure activity relationships, 
which are used qualitatively to estimate human acute and chronic toxicity... 
Estimates of the probable human pharmacokinetics of the chemical are 
made, evaluating absorption, distribution and redistribution, metabolism 
and excretion of the substance.” 
 
In 2004 a Dutch proposal described how chemical prioritisation under REACH could 
additionally incorporate PBT and vPvB properties37. This would mean that after 
consideration of CMR and HPV chemicals, each tonnage category would be sub-divided 
for prioritisation according to PBT and vPvB properties. Chemicals that have these toxic 
                                                 
35 Danish Environmental Protection Agency (2003). Advisory list for self-classification of 
dangerous substances.  
36 Royal Commission on Environmental Pollution (2003). Chemicals in Products — Safeguarding 
the environment and human health. 24th report. Cm 5827. 
37 Note from the Netherlands delegation on “Registration Prioritisation” (2004). Council of the 
European Union Working document 22/04 (ad hoc working party on chemicals). 
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properties could be regulated on the precautionary principle without the need for acute 
toxicity data relating to human health hazards. 
 
5. Existing Data, Read-across and (Q)SARs for Acute Toxicity 
 
The strategy we advocated in our report The Way Forward is highly suited to assessing 
chemicals for acute toxicity, based on: 
 
i. Existing data; 
ii. Read-across and QSARs;  
iii. New data from selected in vitro tests and related computational techniques. 
 
Existing data include human health hazard data from all sources, environmental data 
(including PBT and vPvB status), physico-chemical properties and human exposure 
information.  
 
Many high-priority chemicals will be identified by step [i] alone. For example, a PBT 
chemical would be subject to restriction on the precautionary principle, even in the 
absence of acute toxicity data.  
 
Chemicals without existing acute toxicity or other relevant information would be analysed 
using the approaches in [ii] where appropriate; and/or in [iii] i.e. cell-based and other 
non-animal tests, providing qualitative and quantitative data, as we explain in Section 6.  
 
In 200138, the Environment Council of the European Commission called upon the 
Commission to:  
 
“...explore ways in which chemicals of concern can be identified to allow 
prioritisation for taking action, developing clear and transparent screening 
criteria, essential information requirements, and exploring the use of 
chemical grouping and modelling techniques...” (Council conclusion 37). 
 
The European Commission published a report in November 2004 showing how total 
animal use under REACH could be reduced by the intelligent application and wider 
acceptance of chemical grouping, read-across, (Q)SARs and similar non-animal 
approaches39. The document calculated that REACH would require tests on between 1.7 
– 2.4 million animals (mean 2.1 million) for phase-in substances, if regulatory 
acceptance of chemical grouping, read-across, (Q)SARs and similar estimates was 
optimal. If acceptance of these approaches was minimal, 3.2 – 4.6 million animals (mean 
3.9 million) would be required. Thus maximum use of these ‘intelligent’ techniques could, 
at the most, save up to 3.1 million animals during the 11-year implementation of REACH.  
 
In the specific case of acute toxicity data, the report calculated that these measures 
would reduce the need for new acute toxicity data to two per cent of all phase-in 
                                                 
38 Council of Ministers (2001). Report of the 2355th session of the Council "Environment," 
Luxembourg, 7 June 2001. Luxembourg: Council of Ministers. 
39 K van der Jagt et al (2004). Alternative approaches can reduce the use of test animals under 




The information obtained from these procedures is thus a key step in prioritising and 
classifying chemicals for acute toxicity.  
 
5.1 Existing data 
 
An analysis by the US Environmental Protection Agency (EPA) indicated that acute 
toxicity data are available for 75 per cent of the 2,700 high-production volume 
chemicals41. In fact the US Challenge Program for HPV chemicals has demonstrated 
that 50 per cent of data for all human health endpoints already existed in previously 
unpublished studies, later submitted by industry42.  
 
For many lower tonnage chemicals there will also be acute toxicity results in the 
confidential databases of commercial companies. In fact, it has been estimated that 
acute oral toxicity data (from animals) are already available for most substances in each 
volume band43.  
 
Because of the problems of species differences, existing data from animal studies have 
unproven relevance to humans (see Section 2, above). Therefore it is also critical to 
seek existing human acute toxicity data which provide ‘gold standard’ information. Acute 
lethal concentrations for humans are already known for some chemicals. Additionally, 
records from hospitals, workplaces and poison information centres must be searched for 




For some substances, data are available for structurally related analogues. Where it can 
be done, ‘reading across’ information to predict the toxicity of the untested chemical is 
desirable from practical (cost, time) and animal-welfare points of view.  
 
Read-across is applicable to physico-chemical properties (such as physical form, 
molecular weight, water solubility, partition coefficient, vapour pressure); as well as to 
manufacturing processes; uses; and positive findings from tests that may no longer meet 
modern requirements.  
 
In the UK, more than 10 per cent of new substance notifications have included some use 
of read-across. The biggest impact on animal numbers was on 28-day oral test data, but 
even in the case of acute toxicity, animals were saved. As read-across is more 
extensively practised, the numbers of animals saved will increase. 
 
                                                 
40 This estimate is based on the current version of Annex V which excludes acute toxicity data 
requirements for chemicals in the 1-10 tonnage band. However, see section 5.1. 
41 E-mail from Charles M Auer, 25.6.2003, cited in F Pedersen et al (2003). Assessment of 
additional testing needs under REACH. Publ. European Commission DG JRC. 
42 C Auer (2004). Experience from the US HPV Challenge Program: presented by C Auer (US 
EPA) at the EU-US Transatlantic Conference on Chemicals, April 26-28 2004, Charlottesville, 
USA. 





According to a detailed and recent review of (Q)SARs44: 
 
“Given the limitations in the testing capacity of EU industry, it seems likely 
that the envisaged deadline for obtaining the required information will only 
be met if QSAR approaches are used wherever it is scientifically feasible to 
do so. For example, QSAR models could be used to prioritize chemicals for 
further testing, to identify certain types of toxic hazard (possibly in order to 
derogate from further testing), or to provide estimates of toxic potency for 
use in risk assessments.” 
 
There are several software packages for predicting acute toxicity from chemical 
structure. One example is TOPKAT, a statistically based package comprising several 
QSAR models, including TOPKAT Model Rat Oral LD50. This has been developed using 
experimentally derived LD50 values for about 4,000 chemicals, and assesses acute 
toxicity for a range of chemical classes. There is also a TOPKAT Model for Rat 
Inhalation LC50 that is applicable to five classes of chemicals. The TOPKAT packages 
are used by various European regulatory bodies45. 
 
The Danish Environmental Protection Agency has used (Q)SARs to screen 47,000 
chemicals and identify 9,538 as likely to be acutely toxic by the oral route46. Their 
analysis did not attempt to differentiate between different levels of acute toxicity (e.g. 
very toxic, toxic, harmful), but such data can be gained from in vitro assays (see Section 
6). 
 
The US Environmental Protection Agency and the US International Testing Committee 
(comprising 16 US government organisations, many with regulatory responsibilities) are 
already using SARs to predict acute toxicity for regulatory purposes47. They are also 
using SARs to predict dermal absorption for regulatory applications, and the Danish 
Environmental Protection Agency is using QSARs for the same purpose. 
 
6. Non-Animal Tests for Acute Toxicity 
 
For those chemicals with no available acute toxicity data; and where read-across and 
(Q)SARs are not possible, new testing is required to rapidly identify highly hazardous 
chemicals and to permit classification and labelling.  
 
Non-animal tests — in vitro and other methods — are ideal for this purpose, as 
explained in previous BUAV publications48,49. They allow the prioritisation of the most 
                                                 
44 MTD Cronin et al (2003). Use of QSARs in international decision-making frameworks to predict 
health effects of chemical substances. Environ. Health Perspectives 111:1391-1401. 
45 L Gribaldo et al (2004). Report for establishing the timetable for phasing out animal testing for 
the purpose of the cosmetics directive. Acute Toxicity Chapter. European Commission DG 
Enterprise website: http://pharmacos.eudra.org/F3/cosmetic/AnimalTest.htm 
46 Danish Environmental Protection Agency (2003). Advisory list for self-classification of 
dangerous substances.  
47 MTD Cronin et al (2003). Use of QSARs in international decision-making frameworks to predict 
health effects of chemical substances. Environ. Health Perspectives 111:1391-1401. 
48 BUAV (2001). The Way Forward — Strategy for a future chemicals policy. Publ. BUAV & the 
European Coalition to End Animal Experiments, London. 
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directly toxic chemicals for precautionary regulation in the short term, which is essential 
if human health is to be protected effectively. In the meantime, further and more 
sophisticated non-animal methods must be finalised, as a matter of urgency, for more in-
depth testing of acute toxicity.  
 
The US HPV Challenge Program has shown that for high-production volume 
chemicals50, only six per cent of all data required under REACH had to be obtained by 
new testing.  
 
In the particular case of acute toxicity, the European Commission report estimated that 
only two per cent of all phase-in chemicals would need new tests to be conducted51. 
Acute toxicity data will be required for novel chemicals too. We argue that these data 
can and should be filled by computational methods such as (Q)SARs and by in vitro cell-
based techniques, as explained below. 
 
6.1 Rapid screening for acute toxicity 
 
Computational techniques such as (Q)SARs provide the first screening step for acutely 
toxic chemicals. Packages are available to predict acute toxicity and dermal absorption, 
and these will be sufficient for some chemicals (see Section 5, above). The second 
prioritisation step, if needed, comprises simple tests measuring cytotoxicity in human 
cells.  
 
The Multicentre Evaluation of In vitro Cytotoxicity (MEIC) programme organised by 
Swedish scientists involved dozens of laboratories around the world using 61 cytotoxicity 
methods. Each laboratory used the same reference chemicals for which human acute 
lethal concentration data were available52. They showed that a combination of four 
human cell culture tests53 were practical, rapid, cost-effective and highly predictive of 
human acute toxicity as measured by acute lethal peak bloodstream concentrations.  
 
The four in vitro tests predicted the human data (R2 = 0.77 for 50 chemicals) better than 
rodent LD50 tests predicted lethal doses in humans (R2 = 0.64). These in vitro methods 
have been prevalidated by the MEIC programme54 and would provide a quick and 
informative way of identifying chemicals that are highly and directly toxic. 
 
Additionally, a validation study of two other cytotoxicity protocols for acute toxicity is 
nearly complete. This joint study, undertaken by the US NTP Interagency Center for the 
                                                                                                                                                 
49 BUAV (2004). Endocrine disrupting chemicals — A non-animal testing approach. Publ. BUAV, 
London. 
50 C Auer (2004). Experience from the US HPV Challenge Program: presented by C Auer (US 
EPA) at the EU-US Transatlantic Conference on Chemicals, April 26-28 2004, Charlottesville, 
USA. 
51 K van der Jagt et al (2004). Alternative approaches can reduce the use of test animals under 
REACH. Publ. European Commission DG JRC, Brussels. 
52 C Clemedson et al & B Ekwall et al (2000). MEIC evaluation of acute systemic toxicity parts VII 
& VIII. ATLA 28(Suppl. 1). 
53 The four assay endpoints are protein content, levels of the energy compound ATP, cell shape 
(morphology) and acidity/alkalinity (pH) changes. 
54 L Gribaldo et al (2004). Report for establishing the timetable for phasing out animal testing for 
the purpose of the cosmetics directive. Acute Toxicity Chapter. European Commission DG 
Enterprise website: http://pharmacos.eudra.org/F3/cosmetic/AnimalTest.htm 
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Evaluation of Alternative Toxicological Methods (NICEATM) and ECVAM, has a number 
of aims including55: 
 
“To assess the accuracy of two standardised in vitro cytotoxicity assays for 
estimating rodent oral LD50 values and human lethal concentrations across 
the five Globally Harmonised System categories of acute oral toxicity as 
well as unclassified toxicities.” 
 
The tests involved are neutral red uptake by normal human keratinocytes and by a 
mouse cell line (BALB/c 3T3 fibroblasts), methods already used widely for non-
regulatory purposes. Phases I and II were finished by November 2003 and resulted in 
standardised protocols of sufficient reproducibility to proceed to the final validation stage, 
due to complete at the end of 2004. 
 
Importantly, it was the view of ECVAM even in 2002, prior to formal validation, that these 
tests could immediately be used for priority setting among chemicals56. Therefore, for 
identifying chemicals with a high acute toxicity hazard, several rapid cytotoxicity tests are 
already available for use.  
 
EU funding has been obtained for a collaborative project aimed at the high-throughput 
screening of chemicals within a few years. The new concept is toxicity screening using 
nanodrops of cells, from a range of organs, on microchips. The TOXDROP project aims 
to test 2,600 chemicals before the end of 2005, 2,900 chemicals by 2008, and a total 
24,600 chemicals by 2012. 
 
6.2 Fuller assessment for acute toxicity 
 
The most toxic chemicals can thus be identified and controlled on the basis of rapidly 
acquired in vitro hazard data, using the precautionary principle. Further 
development/validation of more sophisticated non-animal methods, many already 
available, will permit a fuller assessment, incorporating dose/response information as 
well as absorption and metabolism data. 
 
In vitro methods should use human rather than animal cells or tissues, so that species 
variations — in cell permeabilities, enzymes, metabolic rates and routes, and receptors 
— are eliminated. 
 
A full assessment of a chemical’s acute toxicity requires knowledge of its toxicokinetics. 
Toxicokinetics aims to answer several questions, including: Is the chemical absorbed 
(e.g. from the gut, through the skin or via the airways) into the bloodstream? How long is 
it in the circulation? Is it metabolised by the liver or other organs? Does it accumulate 
selectively in certain organs? 
 
In 1996 an ECVAM expert workshop recommended a stepwise strategy for acute toxicity 
testing based primarily on non-animal tests. It combined basal cytotoxicity tests (Section 
6.1) with physico-chemical data; a second tier comprised metabolism of chemicals using 
                                                 
55 In Vitro Cytotoxicity Validation Study – ICCVAM website [visited December 2004]: 
http://iccvam.niehs.nih.gov/methods/ivcytoval.htm 
56 A Worth & M Balls (Eds.) (2002). Alternative (non-animal) methods for chemicals testing: 
Current status and future prospects. ATLA 30(Suppl. 1):1-125. 
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liver cells in the test tube. A third tier involved in vitro studies on specialised target cells 
such as kidney, brain, vascular cells or heart. In vitro data, including metabolism studies, 
were integrated with computer simulations of absorption, metabolism, distribution round 
the body and excretion. Even in 1996 the ECVAM experts stated that the entirely in vitro 
steps in the strategy were sufficient for the classification of chemicals for acute toxicity57 
. Today, these studies are further advanced. 
 
For example, a new project called A-Cute-Tox is being part-funded by the European 
Union. The project involves more than 30 participants from industry, academia and the 
Commission itself. The aim of A-Cute-Tox is to develop a simple and robust in vitro 
testing strategy for prediction of human acute systemic toxicity, which could replace the 
animal acute toxicity tests used today for regulatory purposes. This will include the 
development of new cellular and in silico systems as well as prediction models that 
better relate cell culture concentrations of chemicals to in vivo doses.  
 
The PREDICTOMICS project is intended to develop short-term in vitro assays for long-
term toxicity58. This will be achieved using co-cultures of different cell types, target cell 
transformation, stem cell technology and organotypic cell culture. The project aims to 
identify early mechanistic markers of toxin-induced cell alterations by using integrated 
genomic, proteomic and cytomic analysis; and to establish and prevalidate a screening 
platform (cell systems together with analysis tools) which is unambiguously predictive of 
toxin-induced chronic renal and hepatic disease. 
 
These ambitious and integrated approaches are essential, and promise to revolutionise 
the testing of chemicals and drugs for systemic toxicity. However, in the meantime, there 
are many robust non-animal methods for predicting acute toxic effects, already validated 
or widely in use. Some of these techniques are described below.  
 
6.2.1 Absorption in vitro and in silico 
 
The absorption of a chemical across epithelial barriers (e.g. skin, gut, and lung) can be 
estimated very quickly and cost-effectively on the basis of the octanol/water partition 
coefficient and molecular size59.  
 
There are integrated computational models (e.g. physiologically-based biokinetic 
models) that predict the absorption of chemicals via skin, lung and intestine60. The 
availability of more and better quality data will allow these models to be continually 
improved. 
 
Better predictivity is obtained using human gut cells in culture such as Caco-2 or TC-7 
cells, as a model of the intestinal barrier. The techniques are fast, simple and flexible 
                                                 
57 H Seibert et al (1996). Acute toxicity testing in vitro and the classification and labelling of 
chemicals. ATLA 24:499-510. 
58 http://fp6.cordis.lu/fp6/home.cfm  
59 R Combes et al (2003). An overall strategy for the testing of chemicals for human hazard and 
risk assessment under the EU REACH system. ATLA 31:7-19. 
60 S Coecke et al (2004). Report for establishing the timetable for phasing out animal testing for 
the purpose of the cosmetics directive. Metabolism and Toxicokinetics Chapter. European 
Commission DG Enterprise website: http://pharmacos.eudra.org/F3/cosmetic/AnimalTest.htm 
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and already well established. According to an EU expert group, they provide qualitative 
absorption data without problems of species differences61.  
 
For skin absorption, methods using isolated skin biopsy fragments are already fully 
validated and listed in the OECD test guidelines. Cultures of human lung and airways 
cells (e.g. Calu-3 and 16HBE14o cell lines) have been used in chemical absorption 
studies. If a chemical does not penetrate to the bloodstream it cannot cause systemic 
toxicity and the tests below are not required. 
 
6.2.2 Plasma levels and target organ effects in vitro 
 
On reaching the bloodstream, the pharmacokinetic and pharmacodynamic properties of 
substances are related to their reversible binding to plasma proteins. To estimate likely 
plasma levels of chemicals, protein-binding can be measured rapidly in vitro in multiwell 
plates using human plasma. Pharmaceutical companies use this method routinely in 
their drug discovery and development programmes62.  
 
Predictions of tissue levels of chemicals and their volumes of distribution can be made 
by means of blood-tissue partitioning in vitro. The techniques are familiar to contract 
research organisations and industrial laboratories and have been applied to industrial 
chemicals63 as well as pharmaceuticals. 
 
If necessary, studies of selective effects of chemicals on particular target cells (such as 
kidney, brain, vascular cells or heart) can be conducted in vitro. However, the 
International Workshop on in vitro methods for assessing acute systemic toxicity, held in 
2000, pointed out that it is probably unnecessary to routinely test for all specific organ 
effects in vitro64. Non-animal tests of energy metabolism and to assess a chemical’s 
ability to disrupt epithelial barriers may be sufficient65. 
 
                                                 
61 S Coecke et al (2004). Report for establishing the timetable for phasing out animal testing for 
the purpose of the cosmetics directive. Metabolism and Toxicokinetics Chapter. European 
Commission DG Enterprise website: http://pharmacos.eudra.org/F3/cosmetic/AnimalTest.htm 
62 S Coecke et al (2004). Metabolism in the context of the follow-up of the 7th amendment of the 
cosmetics directive. Chapter by the sub-group of experts on toxicokinetics and metabolism. 
European Commission DG Enterprise website: 
http://pharmacos.eudra.org/F3/cosmetic/AnimalTest.htm 
63 E Artola-Garicano et al (2000). Validation of negligible depletion solid-phase microextraction as 
a tool to determine tissue/blood partition coefficients for semivolatile and nonvolatile organic 
chemicals. Toxicol. Appl. Pharmacol. 166:138-144. 
64 Report of the International Workshop on In Vitro Methods for Assessing Acute Systemic 
Toxicity (2001). Results of an International Workshop organized by the Interagency Coordinating 
Committee on the Validation of Alternative Methods (ICCVAM) and the National Toxicology 
Program (NTP) Interagency Center for the Evaluation of Alternative Toxicological Methods 
(NICEATM). NIH publication 01-4499. Website: 
http://iccvam.niehs.nih.gov/methods/invidocs/finalrpt/finalcov.htm 
65 L Gribaldo et al (2004). Report for establishing the timetable for phasing out animal testing for 
the purpose of the cosmetics directive. Acute Toxicity Chapter. European Commission DG 
Enterprise website: http://pharmacos.eudra.org/F3/cosmetic/AnimalTest.htm 
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6.2.3 Metabolism in vitro 
 
Likely metabolism by liver enzymes can be measured in the test tube using pure 
enzymes, isolated (preferably human) liver cells or liver slices, or subcellular fractions. 
Pharmaceutical companies have been conducting these tests in-house for drug 
development, for many years. The sources of metabolic activity can be varied by gender, 
age and tissue, if necessary, offering potential to assess sub-groups of the human 
population (e.g. children or women). 
 
As another practical approach, FRAME has recommended the development of 
established cell lines genetically engineered to express human metabolic enzymes, and 
states that one laboratory can screen some 200 chemicals per month by means of such 
cell lines66. 
 
6.2.4 Toxicokinetic modelling 
 
Computer models can be constructed to interpret in vitro data and provide answers to 
the toxicokinetic questions. For example, physiologically-based kinetic models67,68 
estimate chemical absorption, distribution, metabolism and excretion, as well as 
dose/response effects. 
 
Other computer models include those such as Symcyp™, developed to simulate human 
pharmacokinetics from simple and commonly available in vitro data69. These include in 
vitro metabolic stability information obtained from recombinantly expressed human 
cytochrome P450s, or characterised human liver microsomes.  
 
7. Summary and Conclusions  
 
Assessing the acute toxicity of chemicals should not involve outdated animal poisoning 
tests.  
 
It is expected that acute toxicity data from animal studies are already available for many 
existing chemicals. These data should be published, although regulators should be 
aware that species differences-hinder extrapolation to humans.  
 
Existing data on acute toxicity in humans, for example from records of accidental 
poisoning, should take precedence over animal data and should be sought from all 
possible sources. Human data, and data obtained from in vitro studies, should be used 
to classify and label chemicals according to the Globally Harmonised System for 
Classification and Labelling. 
 
                                                 
66 R Combes et al (2003). An overall strategy for the testing of chemicals for human hazard and 
risk assessment under the EU REACH system. ATLA 31:7-19. 
67 ME Andersen (2003). Toxicokinetic modeling and its applications in chemical risk assessment. 
Toxicol. Lett. 138:9-27. 
68 P Poulin & FP Theil (2002). Prediction of pharmacokinetics prior to in vivo studies. II. Generic 
physiologically based pharmacokinetic models of drug disposition. J. Pharm. Sci. 91:1358-1370. 
69 NJ Proctor et al (2003). ISEF: an intersystem extrapolation factor for use with recombinant 
cytochrome P450 expression systems. Br. J. Clin. Pharmacol. 55:437-438. 
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In screening large numbers of chemicals to prioritise those in need of further testing, 
chemicals without existing acute toxicity information should first be assessed for 
potential to use read-across techniques from structurally related analogues. (Q)SAR 
models and in vitro cytotoxicity tests (currently under validation) would be applied for the 
identification of highly toxic substances 
 
A fuller assessment of acute toxicity, if needed in some cases, would be based on a 
combination of absorption/penetration assays, test-tube measurements of plasma levels 
and likely target organ distribution; plus in vitro metabolism studies, using toxicokinetic 
modelling. 
 
Not all these techniques have yet been fully validated to regulatory standards but, in all 
cases, validation studies are either underway or are planned. Moreover, there are many 
years of experience with most of them. Their utility is well accepted, especially within the 
drug industry — where their predictions can be confirmed or contradicted in subsequent 
clinical trials. 
 
When considering the current status of new non-animal tests, it is also essential to 
remember that the animal tests for acute toxicity have never been validated to modern 
standards. Their reproducibility between laboratories is so poor that if a validation study 
were to be undertaken, the tests would fail69.  
 
The research required to finalise the necessary non-animal tests should now be 
immediately prioritised by the European Commission, and workshops should be planned 
to disseminate the knowledge required to use data from non-animal methods for 
assessing acute toxicity in chemicals. 
 
                                                 
69 WJ Hunter et al (1979). Intercomparison study on the determination of single administration 
toxicity in rats. J. Assoc. Official Analyt. Chemist. 62:864-873. 
